However, CRC in the obesity / T2D context involves higher morbidity and mortality risk [22, 23], due to induced increase in plasma insulin, IGF-1 and adipo/cytokines that promote cell survival [24], being further increased by treatment with insulin or β-cell secretagogues [25]. This evidence concerns the gene INS and type 2 diabetes mellitus.